BICO company Biosero signs agreement to develop laboratory automation solutions to a value of 28 MUSD

Published: 8-Dec-2023
Research & Development

Biosero, a BICO company and developer of laboratory automation solutions to orchestrate scientific discoveries, has signed an agreement with a global life science company for a total value of 28 MUSD to design and build an automated R&D, hardware and software platform which consists of 5 sub-projects

The project is estimated to run from late Q4 2023 until Q1 2026 and the platform is aimed to shorten time for drug development workflows. The project will run in a ramp-up phase during 2024 and the vast majority of the project will be carried out and invoiced during 2025.
 
“This agreement is a milestone for the Group and it’s our largest project to date. It also shows the strength in Biosero’s offering for laboratory automation solutions and we expect to shorten current timelines for drug development through automation”, says Maria Forss, President and CEO, BICO.

See more

You may also like

Research & Development

Merck and Moderna announce 5-year data for intismeran autogene in combination with KEYTRUDA

Read more
Eight Phase II and Phase III clinical trials are under way across multiple tumour types, including melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma

Trending Articles

  1. FDA and EMA issue guiding principles for AI in drug development The set of ten principles gives broad guidance on AI use in evidence generation and monitoring across all phases of a medicine, from early research and clinical trials to manufacturing and safety monitoring
  2. Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also continuing to expand its EDAPT discovery platform
  3. Studies on HIV and TB reveal tradeoffs for both viruses and immune system in race to survive Research teams have identified mechanisms by which HIV can evade lenacapavir, at the cost of the virus's reproduction and how the immune system can use bacteria to protect against infection — until TB evolved to take advantage
  4. One in ten Britons are using or interested in using GLP-1s for weight loss, according to new research GLP-1 use and interest was more prevalent among women, as well as those who reported difficulties with their finances or who had experienced psychological distress within the previous month
  5. FairJourney Bio launches cryo-EM services to support antibody discovery and biologics design The new offering at the company's San Diego laboratories provides high-resolution structural insights to accelerate antibody discovery, selection and optimisation across the biologics R&D pipeline

Upcoming event

Pharmapack

21–22 January 2026 | Exhibition | Paris, France See all

You may also like

Research & Development

Merck and Moderna announce 5-year data for intismeran autogene in combination with KEYTRUDA

Eight Phase II and Phase III clinical trials are under way across multiple tumour types, including melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma
Manufacturing

Cellistic launches new iPSC-based GMP platforms to boost cell therapy development

Echo-T, Echo-Cardio, and Echo-Endothelial enable scalable immuno-oncology and regenerative therapies
Research & Development

FDA and EMA issue guiding principles for AI in drug development

The set of ten principles gives broad guidance on AI use in evidence generation and monitoring across all phases of a medicine, from early research and clinical trials to manufacturing and safety monitoring
Drug Delivery

Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody

The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development
Research & Development

FairJourney Bio launches cryo-EM services to support antibody discovery and biologics design

The new offering at the company's San Diego laboratories provides high-resolution structural insights to accelerate antibody discovery, selection and optimisation across the biologics R&D pipeline
Research & Development

Studies on HIV and TB reveal tradeoffs for both viruses and immune system in race to survive

Research teams have identified mechanisms by which HIV can evade lenacapavir, at the cost of the virus's reproduction and how the immune system can use bacteria to protect against infection — until TB evolved to take advantage
Research & Development

Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic

Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also continuing to expand its EDAPT discovery platform
Subscribe now